Enveric Biosciences Inc
(ENVB)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,758 | 2,850 | 4,294 | 2,241 | 3,112 |
| TOTAL | $4,166 | $3,307 | $4,835 | $2,735 | $4,338 |
| Non-Current Assets | |||||
| PPE Net | 197 | 241 | 267 | 306 | 368 |
| Intangibles | 0 | 0 | 0 | 42 | 84 |
| TOTAL | $197 | $241 | $267 | $348 | $452 |
| Total Assets | $4,362 | $3,549 | $5,102 | $3,083 | $4,790 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 684 | 1,141 | 771 | 755 | 576 |
| Other current liabilities | N/A | N/A | N/A | N/A | 10 |
| TOTAL | $906 | $1,364 | $1,184 | $1,490 | $839 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $906 | $1,364 | $1,184 | $1,490 | $839 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 597 | 270 | 206 | 206 | 55 |
| Common Shares | 5 | 30 | 25 | 1 | 90 |
| Retained earnings | -112,652 | -110,779 | -108,260 | -106,075 | -102,920 |
| Other shareholders' equity | -581 | -574 | -598 | -595 | -535 |
| TOTAL | $3,456 | $2,185 | $3,918 | $1,593 | $3,951 |
| Total Liabilities And Equity | $4,362 | $3,549 | $5,102 | $3,083 | $4,790 |